Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection

Hepatology Communications

Volumn 2, Issue 5, 2018, Pages 595-606

  George, Jacob ^a   Burnevich, Eduard ^b   Sheen, I Shyan ^c   Heo, Jeong ^d   Kinh, Nguyen Van ^e   Tanwandee, Tawesak ^f   Cheng, Pin Nan ^g   Kim, Do Young ^h   Tak, Won Young ⁱ   Kizhlo, Svetlana ^j   Zhdanov, Konstantin ^k   Isakov, Vasily ^l   Liang, Liwen ^m   Lindore, Pauline ^m   Ginanni, Joy ^m   Nguyen, Bach Yen ^m   Wahl, Janice ^m   Barr, Eliav ^m   Robertson, Michael ^m   Ingravallo, Paul ^m   Talwani, Rohit ^m   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d Pusan National University School of Medicine   (South Korea)

^e National Hospital of Tropical Diseases   (Viet Nam)

^f MAHIDOL UNIVERSITY   (Thailand)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Kyungpook National University School of Medicine   (South Korea)

^j City Center for AIDS and Infectious Diseases Treatment and Prophylaxis   (Russian Federation)

^k S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

^l FEDERAL RESEARCH CENTRE OF NUTRITION   (Russian Federation)

^m MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ELBASVIR; GRAZOPREVIR; PLACEBO; VIRUS RNA;

ADULT; ARTICLE; ASIA; ASIAN; AUSTRALIA; CHINA; CHRONIC HEPATITIS C; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEADACHE; HEPATITIS C VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUSSIAN (PEOPLE); RUSSIAN FEDERATION; SOUTH KOREA; SUSTAINED VIROLOGIC RESPONSE; TAIWAN; THAILAND; VIET NAM;

EID: 85058084943     PISSN: None     EISSN: 2471254X     Source Type: Journal    
DOI: 10.1002/hep4.1177     Document Type: Article

References (27)

1. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(Suppl. 2):61-80
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(Suppl.):S45-S57
3. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-562
4. AASLD/IDSA. HCV Guidance: recommendations for testing, managing, and treating hepatitis C virus. https://www.hcvguidelines.org/. Published September 21, 2017. Accessed December 2017
5. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153-194
6. Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med 2015;30:423-433
7. Omata M, Kanda T, Wei L, Yu M-L, Chuang W-L, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702-726
8. Zepatier (elbasvir and grazoprevir) prescribing information. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2017
9. European Medicines Agency. EPAR summary for the public. Zepatier: elbasvir/grazoprevir. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004126/WC500211238.pdf. Accessed August 2017
10. CATIE. Zepatier for hepatitis C approved in Canada. http://www.catie.ca/en/catienews/2016-01-29/zepatier-hepatitis-c-approved-canada. Accessed August 2017
11. Harper S, McCauley JA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 2012;3:332-336
12. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012;56:4161-4167
13. Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, et al. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother 2016;60:2954-2964
14. Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 2015;59:6922-6929
15. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1075-1086
16. Sulkowski M, Hezode C, Gerstoft J, Vierling J, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1087-1097
17. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1-13
18. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour HM Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-1545. Erratum in: Lancet 2015;386:1824
19. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2:e319-e327
20. Kwo P, Gane E, Peng C-Y, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017;152:164-175.e4
21. Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, et al. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J Hepatol 2016;65:1112-1119
22. Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015;63:564-572
23. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al; C-EDGE CO-STAR Study Group. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 2016;165:625-634
24. Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N, Okanoue T, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol 2017;52:520-533
25. Jin Y-J, Lee J-W, Lee JI, Park SH, Park CK, Kim YS, et al. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patient in Korean population. BMC Gastroenterol 2013;13:74
26. Liu C-H, Liu C-J, Lin C-L, Liang C-C, Hsu S-J, Yang S-S, et al. Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260-1269
27. Dusheiko GM, Manns MP, Vierling JM, Reddy KR, Sulkowski MS, Kwo PY, et al. Safety and tolerability of grazoprevir/elbasvir in patients with chronic hepatitis C (HCV) infection: integrated analysis of phase 2-3 trials [Abstract 712]. Hepatology 2015;62(Suppl. 1):562A